Compare Danaos Corporation (DAC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs TG Therapeutics Inc — how do they compare? Danaos Corporation trades at $138.99 (market cap $2.46B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 3.1× Danaos Corporation's market cap, and Danaos Corporation pays a 2.67% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DAC | TGTX | |
|---|---|---|
Market Cap | $2.46B | $7.64B |
Sector | Technology | Health |
52-Week High | $143.15 | $59.06 |
52-Week Low | $84.05 | $26.94 |
Enterprise Value | $2.44B | $7.84B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DAC trades at $138.94, up 0.45% today, with a bullish technical signal supported by moving averages and oversold RSI indicators. The stock shows strong fundamentals with a low P/E of 4.57, robust net income margin of 51.26%, and consistent earnings beats in recent quarters. Recent news highlights record contracted revenue backlog and dividend declarations, reinforcing positive momentum.
Outlook remains favorable due to undervaluation and earnings strength, but risks include shipping market volatility and capital expenditure pressures. Analyst consensus is split evenly between Buy and Hold, indicating cautious optimism for continued growth amid sector-specific challenges.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
